skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 8,257  for All Library Resources

Results 1 2 3 4 5 next page
Refined by: subject: Life Sciences & Biomedicine remove subject: Oncology remove subject: Patients remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Material Type:
Article
Add to My Research

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

NPJ breast cancer, 2021-01, Vol.7 (1), p.1-1, Article 1 [Peer Reviewed Journal]

The Author(s) 2021. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 2374-4677 ;EISSN: 2374-4677 ;DOI: 10.1038/s41523-020-00208-2 ;PMID: 33397968

Full text available

2
Stakeholders welcome proposal on the European Health Data Space
Material Type:
Article
Add to My Research

Stakeholders welcome proposal on the European Health Data Space

The lancet oncology, 2022-12, Vol.23 (12), p.1492-1492 [Peer Reviewed Journal]

2022 Elsevier Ltd ;2022. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(22)00691-X ;PMID: 36335972

Full text available

3
Opportunities and priorities for breast surgical research
Material Type:
Article
Add to My Research

Opportunities and priorities for breast surgical research

The lancet oncology, 2018-10, Vol.19 (10), p.e521-e533 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30511-4 ;PMID: 30303126

Full text available

4
The importance of patient-reported outcomes in clinical trials and strategies for future optimization
Material Type:
Article
Add to My Research

The importance of patient-reported outcomes in clinical trials and strategies for future optimization

Patient related outcome measures, 2018-01, Vol.9, p.353-367 [Peer Reviewed Journal]

COPYRIGHT 2018 Dove Medical Press Limited ;COPYRIGHT 2018 Dove Medical Press Limited ;2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 Mercieca-Bebber et al. This work is published and licensed by Dove Medical Press Limited 2018 ;ISSN: 1179-271X ;EISSN: 1179-271X ;DOI: 10.2147/prom.s156279 ;PMID: 30464666

Full text available

5
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
Material Type:
Article
Add to My Research

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

The lancet oncology, 2021-08, Vol.22 (8), p.1162-1174 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00302-8

Full text available

6
Global post-mortem tissue donation programmes to accelerate cancer research
Material Type:
Article
Add to My Research

Global post-mortem tissue donation programmes to accelerate cancer research

Nature reviews. Cancer, 2024-05, Vol.24 (5), p.289 [Peer Reviewed Journal]

EISSN: 1474-1768 ;DOI: 10.1038/s41568-024-00683-w ;PMID: 38589555

Digital Resources/Online E-Resources

7
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
Material Type:
Article
Add to My Research

Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial

The lancet oncology, 2021-07, Vol.22 (7), p.1023-1033 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00196-0

Full text available

8
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
Material Type:
Article
Add to My Research

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

The lancet oncology, 2018-10, Vol.19 (10), p.1385-1393 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Oct 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30380-2 ;PMID: 30196031

Full text available

9
Harnessing multimodal data integration to advance precision oncology
Material Type:
Article
Add to My Research

Harnessing multimodal data integration to advance precision oncology

Nature reviews. Cancer, 2022-02, Vol.22 (2), p.114-126 [Peer Reviewed Journal]

2021. Springer Nature Limited. ;Springer Nature Limited 2021. ;ISSN: 1474-175X ;EISSN: 1474-1768 ;DOI: 10.1038/s41568-021-00408-3 ;PMID: 34663944

Full text available

10
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Material Type:
Article
Add to My Research

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

Nature reviews. Drug discovery, 2018-11, Vol.17 (12), p.854-855 [Peer Reviewed Journal]

Copyright Nature Publishing Group Dec 2018 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/nrd.2018.210

Full text available

11
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Material Type:
Article
Add to My Research

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

The Lancet Oncology, 2020-03, Vol.21 (3), p.335-337 [Peer Reviewed Journal]

2020 Elsevier Ltd ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020. Elsevier Ltd ;2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30096-6 ;PMID: 32066541

Digital Resources/Online E-Resources

12
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial
Material Type:
Article
Add to My Research

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial

The lancet oncology, 2019-03, Vol.20 (3), p.352-360 [Peer Reviewed Journal]

2019 Elsevier Ltd ;Copyright © 2019 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30813-1 ;PMID: 30711522

Full text available

13
Translational research in neuroendocrine tumors: pitfalls and opportunities
Material Type:
Article
Add to My Research

Translational research in neuroendocrine tumors: pitfalls and opportunities

Oncogene, 2017-04, Vol.36 (14), p.1899-1907 [Peer Reviewed Journal]

COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Apr 6, 2017 ;Macmillan Publishers Limited, part of Springer Nature. 2017. ;ISSN: 0950-9232 ;EISSN: 1476-5594 ;DOI: 10.1038/onc.2016.316 ;PMID: 27641330 ;CODEN: ONCNES

Full text available

14
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
Material Type:
Article
Add to My Research

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

The lancet oncology, 2020-04, Vol.21 (4), p.508-518 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30074-7 ;PMID: 32135080

Full text available

15
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Material Type:
Article
Add to My Research

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

The lancet oncology, 2019-11, Vol.20 (11), p.1531-1543 [Peer Reviewed Journal]

2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2019. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. ;2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30569-8 ;PMID: 31540791

Full text available

16
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Material Type:
Article
Add to My Research

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

The lancet oncology, 2018-04, Vol.19 (4), p.497-509 [Peer Reviewed Journal]

2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Apr 2018 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30111-6 ;PMID: 29501363

Full text available

17
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Material Type:
Article
Add to My Research

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

The lancet oncology, 2020-04, Vol.21 (4), p.531-540 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(19)30856-3 ;PMID: 32105622

Full text available

18
Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges
Material Type:
Article
Add to My Research

Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges

Cancer letters, 2020-02, Vol.471, p.61 [Peer Reviewed Journal]

2019. Elsevier B.V. ;ISSN: 0304-3835 ;EISSN: 1872-7980 ;DOI: 10.1016/j.canlet.2019.12.007

Digital Resources/Online E-Resources

19
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Material Type:
Article
Add to My Research

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

The lancet oncology, 2020-10, Vol.21 (10), p.1353-1365 [Peer Reviewed Journal]

2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30445-9 ;PMID: 32919526

Full text available

20
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Material Type:
Article
Add to My Research

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

The Lancet (British edition), 2021-09, Vol.398 (10306), p.1157-1169 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00889-8

Full text available

Results 1 - 20 of 8,257  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1996  (10)
  2. 1996 To 2003  (28)
  3. 2004 To 2010  (169)
  4. 2011 To 2018  (1,884)
  5. After 2018  (6,168)
  6. More options open sub menu

Resource Type 

  1. Articles  (8,252)
  2. Books  (3)
  3. Reviews  (1)
  4. magazinearticle  (1)
  5. More options open sub menu

Subject 

  1. Medical Research  (8,102)
  2. Cancer  (3,946)
  3. Humans  (3,782)
  4. Tumors  (3,674)
  5. Medicine, Experimental  (3,617)
  6. Cancer Therapies  (3,530)
  7. Medical Prognosis  (2,899)
  8. Chemotherapy  (2,848)
  9. Metastasis  (2,780)
  10. Care And Treatment  (2,682)
  11. Female  (2,180)
  12. Prognosis  (2,030)
  13. Clinical Trials  (1,798)
  14. Surgery  (1,786)
  15. Male  (1,754)
  16. Health Aspects  (1,682)
  17. More options open sub menu

Language 

  1. Japanese  (720)
  2. Turkish  (28)
  3. Norwegian  (13)
  4. Chinese  (6)
  5. German  (3)
  6. Russian  (2)
  7. Portuguese  (2)
  8. French  (1)
  9. Afrikaans  (1)
  10. More options open sub menu

Searching Remote Databases, Please Wait